# 119-hr-8032: FAIC Act

119-hr-8032, FAIC Act, is a 119th Congress bill sponsored by Rep. Dunn, Neal P. [R-FL-2] (R-FL); status introduced; PRIA reads it as touching household money (as of 2026-09-21).

- Canonical: https://policyrisk.com/legislation/119-hr-8032
- As of: 2026-09-21
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Bill: 119-hr-8032
- Congress: 119
- Title: FAIC Act
- Status: introduced
- Introduced: 2026-03-20
- Sponsor: Rep. Dunn, Neal P. [R-FL-2] (R-FL)
- Cosponsors: 6
- Policy area: Health
- Touches household money: yes
- Last recorded action: 2026-09-21

## Summary

**Separate Medicare payment for certain high-cost cancer drugs in hospital outpatient care.** This bill would require Medicare to stop packaging some cancer drugs into bundled outpatient payments and pay separately for them starting in 2026 when they meet the bill's criteria and cost threshold. - Hospital outpatient departments would receive a separate payment for a qualifying cancer drug when the drug's estimated mean per day product cost meets the annual threshold, which is $350 in 2026. - Qualifying treatments would be drugs or biologics that the Food and Drug Administration approved on or after January 1, 2008 and that do not have transitional pass-through payment status. - The separate payment would equal the greater of an adjusted average sales price, or if that is not available an adjusted wholesale acquisition cost, or if needed the mean unit cost from hospital claims, and the threshold would rise each year with the OPD fee schedule increase factor. *If enacted, the bill would require the Secretary to adjust payments so total Medicare outpatient spending for these treatments remains budget neutral.*

## Cosponsors (6)

- Rep. Soto, Darren [D-FL-9] (D-FL), 2026-03-20T00:00:00.000Z
- Rep. Gottheimer, Josh [D-NJ-5] (D-NJ), 2026-04-14T00:00:00.000Z
- Rep. Kiggans, Jennifer A. [R-VA-2] (R-VA), 2026-04-29T00:00:00.000Z
- Rep. Tenney, Claudia [R-NY-24] (R-NY), 2026-05-14T00:00:00.000Z
- Rep. Rutherford, John H. [R-FL-5] (R-FL), 2026-05-19T00:00:00.000Z
- Rep. Lieu, Ted [D-CA-36] (D-CA), 2026-07-20T00:00:00.000Z

## Provisions PRIA read

- Separate Medicare payments for costly cancer drugs: mixed, high. This bill would, beginning in 2026, require separate Medicare payments for certain high-cost cancer drugs given in hospital outpatient departments. A drug would qualify if it was FDA-approved on or after January 1, 2008, does not have transitional pass-through status, and would otherwise be package…

## Related bills

- 119-hr-9877: Health Equity and Accountability Act of 2026
- 119-hr-6766: Essential Caregivers Act of 2025
- 119-hr-5343: Ensuring Patient Access to Critical Breakthrough Products Act
- 119-hr-1227: Alternatives to PAIN Act
- 119-hr-842: Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
- 119-hr-3946: FIGHT Act of 2025

## Sources
- [119-hr-8032 on Congress.gov](https://www.congress.gov/bill/119th-congress/house-bill/8032)

## Related
- [119-hr-9877: Health Equity and Accountability Act of 2026](https://policyrisk.com/legislation/119-hr-9877)
- [119-hr-6766: Essential Caregivers Act of 2025](https://policyrisk.com/legislation/119-hr-6766)
- [119-hr-5343: Ensuring Patient Access to Critical Breakthrough Products Act](https://policyrisk.com/legislation/119-hr-5343)
- [119-hr-1227: Alternatives to PAIN Act](https://policyrisk.com/legislation/119-hr-1227)
- [119-hr-842: Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage A…](https://policyrisk.com/legislation/119-hr-842)
- [119-hr-3946: FIGHT Act of 2025](https://policyrisk.com/legislation/119-hr-3946)
- [All bills in Congress](https://policyrisk.com/legislation)

Source: PRIA, https://policyrisk.com/legislation/119-hr-8032 (as of 2026-09-21).